Europe’s medical devices industry saw a drop of 8.95% in deal activity in Q1 2021

Led by $880.85m asset transaction with Novasep Holding, Europe’s medical devices industry saw a drop of 8.95% in deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.

 

A total of 89 deals worth $2.99bn were announced for the region during Q1 2021, against the last four-quarter average of 97.75 deals.

Of all the deal types, venture financing saw most activity in Q1 2021 with 46 deals, representing a 51.7% share for the region.

In second place was M&A with 36 deals, followed by private equity deals with seven transactions, respectively capturing a 40.5% and 7.9% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $2.38bn, while venture financing and private equity deals totalled $391.2m and $228m, respectively.

Europe medical devices industry deals in Q1 2021: Top deals

The top five medical devices deals accounted for a 71.8% share of the overall value during Q1 2021.

The combined value of the top five deals stood at $2.15bn, against the overall value of $2.99bn recorded for the quarter.

The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding

2) The $591m acquisition of Oxford Immunotec by PerkinElmer

3) Savaria’s $409.7m acquisition of Handicare Group

4) The $159m acquisition deal with Diagenode by Hologic

5) Sino Biopharmaceutical’s venture financing with Softhale for $110m.